Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments

López-Pelayo, Hugo; Batalla, Albert; Balcells, Mercè; Colom, Joan; Gual, Antoni

doi:10.1017/s0033291714002463

Cited by 45 publications

(31 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[44][45][46] Study retention (87%) was also comparable to previous cessation studies for addiction. 44,[47][48][49][50] Number of pills taken (69%) or adherence rate to study medication was moderate compared to previous pharmacological clinical trials. 45,46,51 Of note, 33% of the progesterone group at week 2 had low progesterone blood levels suggesting missing pills.…”

Section: Discussionmentioning

confidence: 70%

Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial

Allen

Lunos

et al. 2016

NICTOB

View full text Add to dashboard Cite

Introduction: Pregnancy is a strong motivator to quit smoking, yet postpartum relapse rates are high. Growing evidence suggests a role of sex hormones in drug abuse behavior and given the precipitous drop in sex hormones at delivery, they may play a role in postpartum relapse. This pilot study evaluates the feasibility and potential role of exogenous progesterone in postpartum smoking relapse. Methods: This 12-week double-blind placebo-controlled randomized pilot trial randomized 46 abstinent postpartum women to active progesterone (PRO; 200 mg twice a day) versus placebo (PBO) for 4 weeks. Participants were followed for relapse for 12 weeks. Main study outcomes include abstinence (point prevalence), feasibility (compliance per number of clinic visits attended, pill counts and Electronic Data Capture [EDC] completed) and self-reported acceptability. Safety was also measured by depressive symptom scores, adverse events, and breastfeeding. Results: Overall retention rate was 87% at week 12. At week 4, abstinence rates were 75% in the PRO group and 68.2% in the PBO group (p = .75). Medication adherence was 68% and clinic visit attendance was 80%, with no differences by randomization. Depressive symptom scores, adverse events, and breastfeeding did not vary by randomization. Conclusions: Although the study was not powered to evaluate abstinence rates, we did observe a higher prevalence of abstinence at week 4 in the PRO group. Further, exogenous progesterone was well tolerated and did not adversely affect depressive symptoms or breastfeeding. Thus, the results of this pilot study indicate further investigation into progesterone as a postpartum relapse prevention strategy is warranted. Implications: This innovative pilot trial determined the feasibility of delivering exogenous progesterone as a potential prevention of postpartum smoking relapse. We observed high retention and moderate adherence rates, as well as high acceptability among participants. Further, though not statistically significant, more women in the treatment group remained abstinent from smoking during follow-up. This project adds to the growing body of literature on the role of sex hormones in smoking relapse and also provides support for a fully powered clinical trial.

show abstract

Section: Discussionmentioning

confidence: 70%

Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial

Allen

Lunos

et al. 2016

NICTOB

View full text Add to dashboard Cite

show abstract

“…The lack of consensus reflects the variety of measures that are used, a shortage of longitudinal studies across a range of user profiles to assess problematic outcomes, and the lack of a standardized unit to represent dose or consumption amount, as well as subjective differences in defining one's "problematic" use. 24,25 Future work * Bonferroni correction applied, all estimates have been adjusted using bootstrap weights.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of problematic cannabis use in Canada: Cross-sectional findings from the 2013 Canadian Tobacco, Alcohol and Drugs Survey

Leos‐Toro

Rynard

Hammond

2017

Can J Public Health

View full text Add to dashboard Cite

“…Annaheim [4] recently published a review of 44 instruments designed to assess cannabis-related problems and concluded that the CAST, CUDIT-R, and CUPIT are the most appropriate inventories for screening cannabis-related problems. Similarly, López-Pelayo and colleagues [5] conducted a meta-analytic review that identified 25 instruments to assess cannabis use and cannabis-related problems. They also identified the CAST and CUDIT as two of the highest performing inventories for assessing cannabis-related problems.…”

Section: Introductionmentioning

confidence: 99%

Measuring cannabis consumption: Psychometric properties of the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU)

2017

View full text Add to dashboard Cite

ObjectiveWe created the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU) because the current lack of psychometrically sound inventories for measuring these dimensions of cannabis use has impeded research on the effects of cannabis in humans.MethodA sample of 2,062 cannabis users completed the DFAQ-CU and was used to assess the DFAQ-CU’s factor structure and reliability. To assess validity, a subsample of 645 participants completed additional measures of cannabis dependence and problems (Marijuana Smoking History Questionnaire [MSHQ], Timeline Followback [TLFB], Cannabis Abuse Screening Test [CAST], Cannabis Use Disorders Identification Test Revised [CUDIT-R], Cannabis Use Problems Identification Test [CUPIT], and Alcohol Use Disorder Identification Test [AUDIT]).ResultsA six-factor structure was revealed, with factors measuring: daily sessions, frequency, age of onset, marijuana quantity, cannabis concentrate quantity, and edibles quantity. The factors were reliable, with Cronbach’s alpha coefficients ranging from .69 (daily sessions) to .95 (frequency). Results further provided evidence for the factors’ convergent (MSHQ, TLFB), predictive (CAST, CUDIT-R, CUPIT), and discriminant validity (AUDIT).ConclusionsThe DFAQ-CU is the first psychometrically sound inventory for measuring frequency, age of onset, and quantity of cannabis use. It contains pictures of marijuana to facilitate the measurement of quantity of marijuana used, as well as questions to assess the use of different forms of cannabis (e.g., concentrates, edibles), methods of administering cannabis (e.g., joints, hand pipes, vaporizers), and typical THC levels. As such, the DFAQ-CU should help facilitate research on frequency, quantity, and age of onset of cannabis use.

show abstract

Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments

Abstract: Current instruments available for assessing cannabis use disorders need to be further improved. A standard cannabis unit should be studied and existing instruments should be adapted to this standard unit in order to improve cannabis use assessment.

Cited by 45 publications

References 59 publications

Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial

Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial

Prevalence of problematic cannabis use in Canada: Cross-sectional findings from the 2013 Canadian Tobacco, Alcohol and Drugs Survey

Measuring cannabis consumption: Psychometric properties of the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU)

Contact Info

Product

Resources

About